Unconventional Capital Wisdom
Value, long-term horizon, worldly wisdom, growth at reasonable price

Idenix Pharmaceuticals' 2nd Quarter Insight

Recently I wrote an article on Idenix Pharmaceuticals (NASDAQ:IDIX), and since then the company has issued its 2nd quarter earnings with updates on their pipeline and Seth Klarman's Baupost has reported their holdings in Idenix. I will review what was discussed on the call and give my thoughts.

As I discussed in my previous article, safety is a large concern with the development of HCV drugs and poses the largest risk in an investment in Idenix. During the call, the major focus was around the update on IDX719 and pre-clinically held IDX2963.

IDX719 is the drug furthest along Idenix's development pipeline that I believe to be under-appreciated by the market. The pan-genotypic nature of IDX719 is heads and...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details